Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:6172193rdf:typepubmed:Citationlld:pubmed
pubmed-article:6172193lifeskim:mentionsumls-concept:C0596402lld:lifeskim
pubmed-article:6172193lifeskim:mentionsumls-concept:C0041984lld:lifeskim
pubmed-article:6172193lifeskim:mentionsumls-concept:C0042001lld:lifeskim
pubmed-article:6172193lifeskim:mentionsumls-concept:C1704675lld:lifeskim
pubmed-article:6172193lifeskim:mentionsumls-concept:C0243071lld:lifeskim
pubmed-article:6172193pubmed:issue1lld:pubmed
pubmed-article:6172193pubmed:dateCreated1982-3-26lld:pubmed
pubmed-article:6172193pubmed:abstractTextA new uridine analog, 4-hydroxy-1-(beta-D-ribonfuranosyl)-pyridazin-6-one (3-deaza-6-azaUrd), inhibited the growth of L1210 cells in culture, with a concentration to reduce growth rate to 50% of control of 7 X 10(-5) M. After treatment for 24 or 48 h with 5 X 10(-4) M 3-deaza-6-azaUrd, 80% of the cells were unable to resume growth when the analog was removed from the cultures; also, 99% of the cells were killed, as determined by colony formation in soft agar. Studies on the prevention of the cytotoxic effects of 5 X 10(-4) M 3-deaza-6-azaUrd showed that uridine or cytidine gave complete protection. 2'-Deoxycytidine also gave partial protection, but orotic acid or thymidine had no effect on the growth inhibition by 3-deaza-6-azaUrd. These results suggested that growth inhibition by 3-deaza-6-azaUrd might be due to interference in pyrimidine biosynthesis. Activation of 3-deaza-6-azaUrd to its 5'-phosphate derivative appeared to be catalyzed by uridine kinase. 3-Deaza-6-azaUrd was shown to complete with uridine for phosphorylation (Ki = 4.7 mM) and, therefore, to be a possible alternative substrate for uridine kinase from mouse kidney (Km for uridine = 82 microM). The enzyme was partially purified by streptomycin sulfate precipitation, ammonium sulfate fractionation, and gel filtration. This preparation was found to be free of pyrimidine nucleoside phosphorylase and uridine monophosphate kinase.lld:pubmed
pubmed-article:6172193pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6172193pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6172193pubmed:languageenglld:pubmed
pubmed-article:6172193pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6172193pubmed:citationSubsetIMlld:pubmed
pubmed-article:6172193pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6172193pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6172193pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6172193pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6172193pubmed:statusMEDLINElld:pubmed
pubmed-article:6172193pubmed:monthJanlld:pubmed
pubmed-article:6172193pubmed:issn0008-5472lld:pubmed
pubmed-article:6172193pubmed:authorpubmed-author:TownsendL BLBlld:pubmed
pubmed-article:6172193pubmed:authorpubmed-author:WotringL LLLlld:pubmed
pubmed-article:6172193pubmed:authorpubmed-author:BloomerL CLClld:pubmed
pubmed-article:6172193pubmed:issnTypePrintlld:pubmed
pubmed-article:6172193pubmed:volume42lld:pubmed
pubmed-article:6172193pubmed:ownerNLMlld:pubmed
pubmed-article:6172193pubmed:authorsCompleteYlld:pubmed
pubmed-article:6172193pubmed:pagination100-6lld:pubmed
pubmed-article:6172193pubmed:dateRevised2007-11-14lld:pubmed
pubmed-article:6172193pubmed:meshHeadingpubmed-meshheading:6172193-...lld:pubmed
pubmed-article:6172193pubmed:meshHeadingpubmed-meshheading:6172193-...lld:pubmed
pubmed-article:6172193pubmed:meshHeadingpubmed-meshheading:6172193-...lld:pubmed
pubmed-article:6172193pubmed:meshHeadingpubmed-meshheading:6172193-...lld:pubmed
pubmed-article:6172193pubmed:meshHeadingpubmed-meshheading:6172193-...lld:pubmed
pubmed-article:6172193pubmed:meshHeadingpubmed-meshheading:6172193-...lld:pubmed
pubmed-article:6172193pubmed:meshHeadingpubmed-meshheading:6172193-...lld:pubmed
pubmed-article:6172193pubmed:meshHeadingpubmed-meshheading:6172193-...lld:pubmed
pubmed-article:6172193pubmed:meshHeadingpubmed-meshheading:6172193-...lld:pubmed
pubmed-article:6172193pubmed:meshHeadingpubmed-meshheading:6172193-...lld:pubmed
pubmed-article:6172193pubmed:meshHeadingpubmed-meshheading:6172193-...lld:pubmed
pubmed-article:6172193pubmed:meshHeadingpubmed-meshheading:6172193-...lld:pubmed
pubmed-article:6172193pubmed:meshHeadingpubmed-meshheading:6172193-...lld:pubmed
pubmed-article:6172193pubmed:year1982lld:pubmed
pubmed-article:6172193pubmed:articleTitleCytotoxicity of a new uridine analog, 4-hydroxy-1-(beta-D-ribofuranosyl)-pyridazine-6-one, and its interaction with uridine kinase.lld:pubmed
pubmed-article:6172193pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:6172193pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed